Sprint Bioscience AB has entered into an agreement to use Lilly Tunelab, Eli Lilly and Co.’s AI-based drug discovery platform, to support work on its research portfolio.

Thyora Therapeutics has launched with a mission to leverage next-generation covalent chemistry to accelerate clinical translation and create therapies for unmet medical needs.

Outer membrane vesicles (OMVs), naturally released by gram-negative bacteria, are promising platforms for mucosal vaccines due to their immunostimulatory properties and ability to display antigens. Abera Bioscience AB previously developed an OMV platform using genetically engineered bacteria with covalent antigen decoration via Spycatcher/Tag technology.

The HIV vaccine field is increasingly focusing on inducing broadly neutralizing antibodies (bNAbs) that can recognize the virus’s genetic diversity. Recent experimental approaches include germline-targeting vaccines, sequential immunization strategies, mRNA-based immunogens, and nanoparticle platforms displaying engineered HIV envelope (Env) trimers. Several studies published in 2025 and 2026 how these designs guide antibody maturation in humans and generate broad neutralizing responses in nonhuman primates, although no HIV vaccine has yet demonstrated protective efficacy in large clinical trials.

Immitra Bio GmbH has completed a CHF2.4 million (US$ 3 million) pre-seed financing round as it advances development of a platform for scalable, one-time curative in vivo gene editing therapies based on its mutation-agnostic gene editing technology and digital target identification platform.

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution.

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In preclinical models of HER2 and EGFR co-expressing pancreatic, breast and gastric tumors, sequential administration of the ADC and the second antibody was better at shrinking tumors than either ADC monotherapy or a combination of antibody and ADC treatment.

Sightera Biosciences BV announced it has raised €3 million (US$3.5 million) in pre-seed funding. The funding will be used to extend the company’s platform technology and asset portfolio, including its lead program in oncology, SIGHT-001.

Human cytomegalovirus (CMV) is a clinical challenge in infants and immunocompromised individuals, since no licensed vaccine exists. Vaccine development is complex due to several factors, including viral latency, genomic complexity and immune evasion, among others. Evaxion A/S recently presented data on its proprietary AI-immunology platform used to create the EVX-V1 vaccine for CMV infection.

While biomedical resources in the form of specialized tools, hundreds of thousands of published papers and huge repositories of ‘omics, health records and other data, are growing exponentially, discovery is getting slower and more expensive. That is the perspective from which scientists at Stanford University approached the development of their artificial intelligence (AI) research assistant Biomni.